ANGO heads into the back half of fiscal 2026 with fresh analyst conviction behind it — two buy-side target upgrades on the day of results, a stock now up 7% on the month, and options markets suddenly demanding far more downside protection than they have all year.
The analyst story is the clearest positive signal this week. Both HC Wainwright and Canaccord Genuity raised their price targets on July 15, the day after AngioDynamics released quarterly results — HC Wainwright moving to $19 from $16, Canaccord to $20 from $16. The consensus mean now sits at $20 against a stock price of $13, implying more than 50% upside by Street math. The bull case centres on the Auryon atherectomy platform, which management says is expanding into both in-hospital and out-of-hospital settings while lifting average selling prices. The path to 52.5% gross margins — through manufacturing efficiency gains and a revenue mix shift toward higher-value Med-Tech products — is the operational bet the bulls are making.
The bear case is real, though. Tariff headwinds of $4–6 million loom over the second half, and rising raw material costs are expected to pressure H2 inventory margins. The EV/EBITDA multiple, running near 29x, has compressed roughly 35% over the past 30 days as the stock recovered — meaning the multiple is moving in the wrong direction for value buyers even as the price rises. The PE remains deeply negative, reflecting a company still running operating losses, and the EPS momentum factor score ranks in just the 5th percentile over both 30 and 90 days. Where the data is constructive is on EPS surprise — that ranks in the 88th percentile, suggesting beats happen, even if the trend in forward estimates remains soft.
Options markets caught a notable jolt on the results day itself. The put/call ratio jumped to 0.85 on July 14 — more than double where it had been running for the prior two weeks, and nearly four standard deviations above its 20-day average of 0.41. That's the most defensive single-session reading relative to recent history all year, though it sits well inside the 52-week high of 2.47. One day does not make a trend, and the prior weeks had been unusually call-heavy. But the abrupt shift suggests at least some participants used the earnings event to add downside hedges rather than chase the opening strength. Short interest, by contrast, tells a much less charged story — SI has fallen 18% over the past week to 3.4% of the free float, the lightest positioning in more than six weeks. Borrow costs are minimal at around 0.51%, and availability is extraordinarily loose at nearly 2,900% — meaning there is no shortage of shares to borrow for anyone who wants to press the short side. The lending market offers no squeeze setup here.
Institutional ownership adds some texture to the ownership picture. BlackRock holds 8.8% and added shares in the most recent quarter. Point72 built a 7.6% position as of March, adding over 356,000 shares in that period. Broadfin Capital and Armistice Capital — both active healthcare specialists — were also adding in Q1. That cluster of specialist healthcare funds and a large-cap passive anchor at the top of the register gives the float a reasonably firm institutional foundation.
Peer context cuts against ANGO's relative strength this week. Most correlated names in the medical device space had a rough five days — IRTC fell 10%, COO dropped nearly 5%, and BAX shed 4.6%. ANGO's flat-to-slightly-down week looks considerably better by comparison, and the month-long 7% gain stands in contrast to what has been a broadly difficult patch for mid-cap medtech. Whether the next quarterly print — scheduled for October 2 — confirms that the Auryon ramp and margin story is running ahead of the tariff drag, or falls short, is the question the upgraded targets are betting on.
See the live data behind this article on ORTEX.
Open ANGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
